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Abstract
Background: Ιn multiple sclerosis (MS), axonal damage leads to permanent neurological disabilities and the
spreading of the autoimmune response to axonal antigens is implicated in disease progression. Experimental
autoimmune encephalomyelitis (EAE) provides an animal model that mimics MS. Using different EAE models,
we investigated the pathophysiological basis of epitope spreading to neurofascin, a protein localized at the
node of Ranvier and its regulation by non-MHC genes.
Methods: We used two different EAE models in DA rat; one which is induced with myelin oligodendrocyte
glycoprotein (MOG) which leads to disease characterized by profound demyelination, and the second which is
induced with myelin basic protein (MBP) peptide 63–88 which results in severe central nervous system (CNS)
inflammation but little or no demyelination. We determined anti-neurofascin antibody levels during the course
of disease. Furthermore, the anti-neurofascin IgG response was correlated with clinical parameters in 333 (DAxPVG.1AV1) x
DA rats on which we performed linkage analysis to determine if epitope spreading to neurofascin was affected
by non-MHC genes.
Results: Spreading of the antibody response to neurofascin occurred in demyelinating MOG-induced EAE but
not in EAE induced with MBP peptide 63–88. Anti-neurofascin IgG levels correlated with disease severity in
(DAxPVG.1AV1) x DA rats, and a genomic region on chromosome 3 was found to influence this response.
Conclusions: Inter-molecular epitope spreading to neurofascin correlates with disease severity in MOG-EAE is
dependent on extensive demyelination and is influenced by non-MHC genes. The findings presented here may shed
light on factors involved in the severity of MS and its genetics.
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Background
Multiple sclerosis (MS) is a chronic inflammatory dis-
ease characterized by demyelination and axonal dam-
age leading to chronic neurological deficits. A role of
B cells and autoantibodies in disease pathogenesis is
supported by numerous observations derived from a
wide range of clinical, pathological, and experimental
studies. In particular, oligoclonal bands (OCB) are
found in the cerebrospinal fluid (CSF) in the majority
of MS patients, implying involvement of intrathecal
synthesis of immunoglobulin and B cells [1] even
though the antigenic specificity of this response re-
mains unclear [2]; plasma exchange can lead to disease
amelioration in some patients [3]; histopathological
studies demonstrate that many lesions are associated
with immunoglobulin and complement deposition [4];
ectopic B cell follicles are present in the meninges of pa-
tients with secondary progressive MS and are implicated
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in driving disease activity in the underlying paren-
chyma [5, 6]; demyelinating and axopathic autoanti-
bodies can be identified in patient sera; and finally,
phase II studies with anti-CD20 antibodies targeting
B cells, such as Rituximab, have a profound effect on
disease activity in patients with relapsing-remitting
disease [7].
Axonal injury and loss are now recognized to be
the cause of permanent neurological disability in MS
[8, 9], but the molecular mechanisms responsible for
this axonal pathology remain unclear. Evidence is
now available implicating contributions from invading
inflammatory cells [10], complement [11], glutamate
excitotoxicity [12], loss of trophic support provided
by myelinating oligodendrocytes [13], and axopathic
autoantibodies [14]. The relative contribution of these
pathomechanisms in MS remains controversial but
using a proteomics-based approach, Mathey et al.
identified neurofascin as a potential target for an axo-
pathic autoantibody response [14]. Anti-neurofascin
antibody titers were more pronounced in secondary
progressive MS than in relapsing-remitting MS, and
adoptive transfer of neurofascin-specific antibodies
caused rapid worsening of experimental autoimmune
encephalomyelitis (EAE), an animal model for MS.
This clinical effect was associated with deposition of
neurofascin-specific antibody and complement at nodes of
Ranvier resulting in inhibition of neurotransmission and
axonal damage [14].
Neurofascin is just one among the increasing num-
ber of myelin and non-myelin antigens now impli-
cated in the pathogenesis of MS, but the mechanisms
by which these autoimmune responses are initiated
are still elusive. Attempts at resolving this problem
are confounded by epitope spreading, the ability of
the initial pathogenic response to one autoantigen to
initiate secondary responses to other tissue-specific
targets. This phenomenon has been described exten-
sively in EAE, in which epitope spreading is associ-
ated with induction of clinical relapses [15]. In the
case of neurofascin, we hypothesized epitope spread-
ing to involve this autoantigen would be most likely
in disease models in which there is extensive demye-
lination and axonal injury. This is not the case in the
classical models of EAE induced by immunization
with myelin basic protein (MBP) or MBP peptides, a
protocol that results in a monophasic neuroinflamma-
tory disease in rats that is associated with little or no
demyelination [16, 17]. In contrast, immunization with
myelin oligodendrocyte glycoprotein (MOG) leads to a re-
lapsing disease with extensive demyelination [18, 19], a
situation predicted to enhance availability of neurofascin
epitopes to elicit a secondary response. We therefore in-
vestigated if there was a difference in epitope spreading to
neurofascin in these two models of EAE in DA rat
and if there was any correlation with disease severity.
We report that the induction of EAE using recombin-
ant MOG is associated with the development of a
neurofascin-specific autoantibody response, which is
not observed in animals with MBP peptide 63–88 induced
EAE. Screening for this response in a (DAxPVG.1AV1) x
DA (hereafter referred as DA backcross) population im-
munized with MOG revealed that neurofascin-specific
antibody levels which correlate with disease severity
and that this antibody response was dependent on non-
MHC genes. These observations are of great import-
ance in view of the current attempts to extend the
study of MS genetics to explore mechanisms determin-
ing disease severity.
Methods
Ethics statement
All experiments in this study were approved and per-
formed in accordance with the guidelines from the
Swedish National Board for Laboratory Animals and the
European Community Council Directive (86/609/EEC)
under the ethical permits N338/09, N298/11, and N478/
12 entitled “Genetic regulation, pathogenesis and ther-
apy of EAE, an animal model for multiple sclerosis”,
which was approved by the North Stockholm Animal
Ethics Committee (Stockholms Norra djurförsöksetiska
nämnd). The rats were tested according to a health-
monitoring program at the National Veterinary Insti-
tute (Statens Veterinärmedicinska Anstalt, SVA) in
Uppsala, Sweden.
Animals
The DA rats were purchased from Harlan Laboratories
(Harlan Laboratories, Venray, The Netherlands). The
animals were housed in polystyrene cages containing
aspen wood shavings and had free access to standard
rodent chow and water. They were immunized with ei-
ther MOG or MBP63–88 for induction of EAE and used
for T cell proliferation assays ( see the “Thymidine in-
corporation assay” for description). Additionally, a DA
backcross population was established between DA/Kini
and MHC-identical PVG.1AV1 strains, as described
previously [20]. To create the F1 generation, four
breeding pairs with DA female founders were estab-
lished. The N2 generation was bred from eight breeding
pairs, with DA females or males crossed to F1 males
and females, respectively. Four N2 litters, 421 backcross
rats (213 females and 208 males) were subjected to
MOG-EAE induction. Assessment of antibodies against
neurofascin at day 35 after MOG immunization was
performed in 333 (174 females and 159 males) DA
backcross rats as 88 of the DA backcross rats either
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died during EAE or sacrificed according to the ethical
considerations.
Induction and determination of disease phenotypes
DA female age-matched rats between 11 and 12 weeks
of age were anesthetized with isoflurane (Forene; Abbott
Laboratories, Chicago, IL, USA) and immunized by a
single subcutaneous injection in the dorsal base of the
tail with 200 μl inoculum containing either one of the
following five preparations: (a) 20 μg rat recombinant
MOG (aa 1–125 from the N terminus, expressed in
Escherichia coli and purified to homogeneity by chelate
chromatography, hereafter denoted MOG) in phosphate-
buffered saline (PBS) (Life Technologies, Paisley, Scotland)
emulsified (1:1) with incomplete Freund’s adjuvant (IFA)
(Sigma-Aldrich, St Louis, MO, USA), (b) 100 μg guinea
pig MBP peptide (aa 63–88 from the N terminus with se-
quence AARTTHYGSLPQKSQRSQDENPWHF, here-
after denoted MBP63–88) purchased from GL Biochem
(Shanghai) Ltd. (Shanghai, China) in PBS emulsified
(1:1) with complete Freund’s adjuvant (CFA) (Sigma-
Aldrich, St Louis, MO, USA) containing 0.5 mg Mycobac-
terium tuberculosis (MTB) (DIFCO Laboratories, Detroit,
Michigan, USA), (c) 50 μg recombinant rat neurofas-
cin 155 (hereafter denoted rrNF) (R&D systems,
Minneapolis, MN, USA) in PBS emulsified (1:1) with
CFA containing 1 mg MTB, (d) IFA, or (e) CFA con-
taining 0.5 mg M. tuberculosis.
In another experiment, female and male DA backcross
rats between 8 and 16 weeks of age were anesthetized
with isoflurane and each animal received a 200-μl inocu-
lum containing MOG (females 12.5–40 μg and males
25–80 μg) in PBS emulsified (1:1) with IFA.
The rats were weighed and monitored daily for clinical
signs of EAE, from day 7 until the day of sacrifice at day
56 post immunization (p.i.) for the DA rats and day 35 p.i.
for the DA backcross rats. The clinical scoring scale was
as follows: 0, no clinical signs of EAE; 1, tail weakness or
tail paralysis; 2, hind leg paraparesis or hemiparesis; 3,
hind leg paralysis or hemiparalysis; 4, tetraplegia or mori-
bund; and 5, death. The following clinical parameters were
used: EAE incidence, clinical signs for more than 1 day;
onset of EAE, the first day clinical signs were observed;
maximum EAE score, the highest clinical score observed
during disease; cumulative EAE score, the sum of all daily
clinical scores; duration of EAE, the number of days with
EAE; and weight loss (WL0), which is a quantitative trait
considered to correlate well with a clinical EAE course
and that represents (weight at day 0 p.i.—minimum
weight during the experiment)/weight at day 0 p.i.
Serum collection
To determine antibody levels, blood was collected for
serum at day 12, day 26, day 41, and day 56 p.i. in the
DA rats and at day 12 and 35 p.i. in the DA backcross
rats. The rats were anesthetized under isoflurane, and
the blood was collected by tail bleeding; at the day of
sacrifice, the rats were euthanized under CO2 and the
blood was collected through cardiac puncture. The
blood was centrifuged at 3600 rpm at 4 °C for 20 min,
and serum was collected and preserved at −20 °C until
ELISA analysis.
Anti-neurofascin IgG and IgG isotypes determination
ELISA was used to determine anti-rrNF IgG and
isotype-specific for IgG1 and IgG2b, anti-MOG IgG,
and anti-MBP63–88 IgG. Furthermore, to assess specificity
of anti-rrNF IgG antibodies, we measured anti-human
neurofascin 155 (hNF155), anti-human neurofascin
186 (hNF186), anti-C-reactive protein (CRP) IgG and
anti-interleukin 9 receptor (IL-9R) IgG by ELISA. To
investigate cross-reactivity between anti-rrNF IgG and
anti-contactin-2 (TAG-1), anti-TAG1 IgG antibodies
were assessed by the same method.
Ninety-six-well ELISA plates (Sigma-Aldrich, Roskilde,
Denmark) were coated with 10 μg/ml of either of the
following: rrNF (R&D systems), hNF155, hNF186 (both
produced as described in Ng et al. Neurology 2012), re-
combinant rat MOG, guinea pig MBP63–88, and recom-
binant rat TAG-1 (R&D systems), each one of them
diluted in 0.1 M NaHCO3 (pH 8.2) (100 μl/well). The
coated plates were stored overnight at 4 °C. The plates
were washed twice with PBS/0.05 % Tween-20, and free
binding sites were blocked with 5 % fat-free milk in
PBS/0.05 % Tween-20 for 1 h at room temperature (RT).
The rat sera was diluted 1:200 (for anti-rrNF IgG, IgG1,
and IgG2b isotypes, for anti-MOG IgG in MBP63–88-
EAE rats, for anti-MBP63–88 IgG in MOG-EAE rats, for
anti-hNF155 IgG, for anti-hNF186 IgG, for anti-CRP
IgG, and for anti-IL-9R IgG), 1:1000 (for anti-MOG IgG
in MOG-EAE rats and for anti-MBP63–88 IgG in MBP63–
88-EAE rats) in PBS/1 % milk and incubated in dupli-
cates in plates for 1 h at RT. The plates were washed
and incubated for 1 h at RT with rabbit anti-rat IgG
(1:2000), IgG1 (1:1000), and IgG2b (1:2000) (Nordic,
Tilburg, The Netherlands). Unbound antibodies were
removed by washing prior to addition of a peroxidase-
conjugated goat anti-rabbit antiserum (Nordic) diluted in
PBS/0.05 % Tween-20 (1:10,000). After 30 min of incuba-
tion, the plates were washed extensively and bound anti-
bodies were visualized with 3,3′,5,5′-tetramethylbenzidine
(Sigma). The reaction was stopped by addition of 1 M
HCl after 5–10 min in darkness, and the optical density
(OD) was read at 450 nm using an Emax Microplate
Reader (Molecular Devices, Sunnyvale, USA). Seven two-
fold dilutions of serum samples from rats with high levels
of each antibody detected in a pilot study were included
on each plate to create a standard curve and to permit
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interplate comparisons. The serum samples from the
animals immunized with IFA, CFA, or rrNF were also
included in each ELISA plate as negative (serum from
IFA- and CFA-immunized rats) and positive controls
(serum from rrNF-immunized rats).
In the MOG- and MBP63–88-immunized DA rats, we
considered the serum specimens to be antibody-positive
when the optical density exceeded the cut-off value,
which was set at 5 standard deviations (SD) above the
mean optical density in serum specimens from IFA- or
CFA-immunized DA rats, respectively.
In the DA backcross population, due to the absence of
IFA-immunized control animals, we arbitrarily chose to
use a more stringent cut-off for antibody positivity. We
considered serum specimens to be antibody-positive
when OD exceeded the cut-off value, which was set at
15 % of the serum specimens exhibited the highest anti-
body values. The stringent threshold was also based on
testing different cut-off values, e.g., when the serum
specimens were considered positive if they exceeded 10
or 20 % of specimens with the highest OD values, and
the outcome in our analysis did not differ. Furthermore,
OD values lower than the cut-off of 15 % that we set in
the analysis clearly represented a background signal.
Adsorption of anti-rrNF IgG antibodies
To examine if there is cross-reactivity between anti-
rrNF IgG and anti-TAG1 IgG antibodies, we depleted
anti-rrNF antibodies in selected serum samples by per-
forming consecutive adsorptions to plate-bound rrNF.
Subsequently, we compared the response against TAG-
1 between intact serum and anti-rrNF IgG antibody-
depleted serum.
Tissue collection and preparation
To determine T cell response, 28 days after MOG
immunization, the DA rats were euthanized under
CO2 and the spleen and deep cervical lymph nodes
were collected. The spleen and lymph nodes were
placed in DMEM (Gibco-BRL, Grand Island, NY),
enriched with 10 % fetal calf serum, 1 % glutamine,
1 % penicillin-streptomycin, and 1 % pyruvic acid (all
from Life Technologies, Paisley, Scotland) before be-
ing mechanically separated by passing through a mesh
screen with the bolus of a syringe. Erythrocytes were
removed from the spleen samples by lysis with ACK
buffer (Gibco, Invitrogen, Karlsruhe, Germany). The
samples were resuspended in PBS, and cell numbers
were assessed by counting with trypan blue as a dead
cell exclusion dye.
Thymidine incorporation assay
To assess T cell proliferation, 400,000 splenocytes/well
and 100,000 deep cervical lymph node cells/well were
plated in 96-well round bottom plates (Nunc, Roskilde,
Denmark) in triplicates. The cells were stimulated with
either of the following: medium, 20 μg/ml MOG, 20 μg/
ml rrNF (R&D systems), or 1 μg/ml concanavalin A
(ConA) (Sigma-Aldrich) for 72 h at 37 °C and 5 % CO2.
Eighteen hours before collection, 1 mCi of H3 radio-
active thymidine (GE Halthcare, Bucks, UK) was added
to each well. The cells were harvested using a Wallac
Tomtec (Perkin, Elmer, Waltham, USA) and isotope in-
corporation was measured using a Wallac TriLux 1450
Microbeta (Perkin Elmer).
Genotype
Genotyping of 333 DA backcross rats was performed
on DNA extracted from the tail tip/ear according to a
standard protocol. Genotypes were determined by PCR
amplification of 137 microsatellite markers. Fluorophore-
conjugated primers were used (Applied Biosystems,
Eurofins MWG, Operon, Foster City, CA, USA), and
PCR products were size fractionated using an electrophor-
esis capillary sequencer (ABI3730, Applied Biosystems).
The genotypes were analyzed using the GeneMapper soft-
ware (v. 3.7, Applied Biosystems), and two independent
observers manually evaluated all genotypes.
Statistical analysis
Spearman’s rank correlations between antibody levels
and clinical EAE phenotypes or between antibody levels
against other antigens were calculated in GraphPad
Prism 5.0 (Graph Pad, San Diego, CA, USA). Differences
in T cell response between medium and neurofascin
stimulation were calculated in GraphPad Prism 5.0 using
non-parametric Mann-Whitney U test. In the DA back-
cross population, antibody levels between healthy and
sick groups and EAE clinical parameters between anti-
neurofascin IgG(−) and anti-neurofascin IgG(+) groups
were compared using non-parametric Mann-Whitney U
test in GraphPad Prism 5.0.
Linkage analysis
The genetic map was defined using publicly available
genome sequence (http://oct2012.archive.ensembl.org/
index.html). Linkage analysis was performed with the
statistical software R/qtl version 2.11.1. [21]. A single-
quantitative trait loci (QTL) model analysis was
performed using Haley-Knott regression model on
transformed OD values, and “weight at day 0” and “sex”
were used as additive covariates. Permutation tests
(N = 1000) were performed to determine the threshold
levels for significant linkage. Differences in allelic effects
of the QTL were analyzed with the non-parametric
Mann-Whitney U test using GraphPad Prism 5.0.
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Results
Epitope spreading to neurofascin occurs in MOG-EAE
To assess whether an antibody response to neurofascin
could arise secondary to a response to another central
nervous system (CNS) antigen, we used the two most
prevalent EAE models in DA rats, namely immunization
with MOG in IFA and with MBP63–88 in CFA.
All rats immunized with MOG developed a MOG-
specific IgG response. This was already detected at
day 12 p.i. and persisted throughout the course of the
disease (Additional file 1: Table S1). Anti-rrNF IgG
antibodies could also be detected in these sera, but
only at a late stage of MOG-induced EAE; 16 out of
31 (52 %) MOG-immunized rats were seropositive for
rrNF-specific IgG antibodies at day 26 p.i. In most of
these rats, this anti-rrNF antibody response persisted
until day 41 p.i. and in some cases, titers remained
high until the rats were sacrificed at day 56 p.i. In
four animals, rrNF-specific antibodies were already
detected on day 12, but the titers were very low in
three of them, implying that epitope spreading tends
to occur during later phases of disease (Fig. 1 and
Additional file 1: Table S1). In contrast, fewer rats, 10
out of 31 (32 %), with MOG-induced EAE developed
an antibody response to MBP63–88. Moreover, this low
titer response was generally only observed at single
time points, with the exception of two rats with high
levels at two time points (Additional file 1: Table S1).
Interestingly, anti-rrNF IgG response did not correlate
with anti-MBP63–88 IgG response (Additional file 2:
Figure S1).
In contrast to MOG-induced EAE, we observed little
or no antibody to rrNF in the DA rats with MBP63–88-
induced EAE (Additional file 3: Table S2). All MBP63–88-
immunized rats developed an acute monophasic disease
with symptoms reaching maximum severity around day
12 p.i., after which the animals slowly recovered over the
next 10 to 14 days (Fig. 2). All animals developed high
titer antibody responses to MBP63–88 but only one devel-
oped a transient, low titer response to rrNF (Additional
file 3: Table S2). Epitope spreading to MOG was some-
what more pronounced in that 16 % (4 of 25) of the rats
immunized with MBP63–88 developed a MOG-specific
IgG response by day 56 p.i. (Additional file 3: Table S2).
Validation of anti-neurofascin reactivity
To validate the data we obtained using a commercially
available rrNF, we screened the rat sera for reactivity to
hNF155 and hNF186. This revealed a similar pattern of
reactivity to all three neurofascin variants (Additional
file 4: Figure S2a and b). Furthermore, to eliminate the
possibility that this response might include a significant
component directed against their C-terminal histidine
tags, we compared reactivity to rrNF and two other re-
combinant proteins generated using the same cell line
and carrying an identical histidine tag (CRP and IL-9R;
R&D Systems). Low levels of reactivity to CRP and IL-9R
were detected in some animals but their correlation to the
response to rrNF was minimal (Additional file 4: Figure
S2c and d) implying the response to rrNF does not include
a significant component directed against its histidine tag.
Nonetheless this does not exclude the possibility that
the antibody response to rrNF cross reacts with other
members of the Ig superfamily of cell adhesion mole-
cules; one candidate being TAG-1, a potential MS auto-
antigen [22] that exhibits approximately 30 % sequence
similarity to neurofascin. To check for cross-reactivity
with TAG-1, we first depleted MOG-EAE rat serum of
anti-rrNF IgG antibodies by consecutive adsorptions to
plate-bound rrNF and then, investigated the reactivity
against TAG-1 using non-depleted serum as control.
We observed no reactivity against TAG-1 in the anti-
rrNF IgG-depleted samples whereas non-depleted sam-
ples displayed anti-TAG-1 IgG response (Additional file
5: Figure S3), implying that antibodies against neurofas-
cin can also bind to TAG-1.
Taken together, our experiments show that detec-
tion of anti-rrNF IgG antibodies as measured by
ELISA is specific in that the response cross-reacts
with hNF155 and hNF186 and does not bind the re-
combinant proteins His-Tag. However, our data sug-
gests that this antibody response cross-reacts with
another nodal antigen, TAG-1.
MOG-induced EAE is associated with T cell reactivity to rrNF
T cells facilitate B cell responses and are important for
the induction of immunoglobulin isotype switch. In
order to examine if there is a neurofascin-specific T cell
response in the MOG-immunized animals, we collected
day 12 day 26 day 41 day 56
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Fig. 1 Anti-rrNF IgG response over time in DA rats in MOG-EAE.
Thirty-one DA rats were immunized with MOG in IFA, and anti-rrNF
IgG levels were assessed in the sera at different time points (day 12,
day 26, day 41, and day 56) after immunization by ELISA. The sera were
diluted 1:200. Data are presented in OD values. Only anti-rrNF IgG(+)
rats are included in the graph
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the spleen and deep cervical lymph nodes of the DA rats
28 days after MOG immunization. The cells were stimu-
lated with a medium, MOG, rrNF, or ConA (as a
positive control), and T cell proliferation was mea-
sured by thymidine incorporation. Splenocytes from
the MOG-immunized donors exhibited a significant
recall response to rrNF (p < 0.05) (Fig. 3), confirming
that MOG-induced EAE is associated with low, but
significant T cell reactivity to neurofascin.
Epitope spreading to involve neurofascin is genetically
regulated and is associated with more severe clinical disease
Our primary data indicate that MOG-induced EAE is as-
sociated with epitope spreading leading to the develop-
ment of a potentially pathogenic autoantibody response.
To determine whether this phenomenon was genetic-
ally regulated. we immunized 333 rats from a DA
backcross population with MOG in IFA of which 197
developed clinical disease. This not only allowed us to
perform linkage analysis with respect to the rrNF-specific
autoantibody response but also provided sufficient num-
bers of animals to explore potential correlations between
this antibody response and disease severity. Linkage ana-
lysis of 174 female DA backcross rats at day 35 identified
a QTL on chromosome 3 with a logarithm of the odds
(LOD) score of 3.3 that is associated with the rrNF-
specific IgG2b response (Fig. 4a). Further analysis plotting
the allelic effect at the peak marker (D3Rat139) of the
QTL confirmed that DA susceptibility alleles were respon-
sible for driving this response (Fig. 4b). The confidence
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Fig. 2 EAE course in MOG- and MBP63–88-immunized DA rats. The DA rats were immunized with 20 μg recombinant MOG in PBS emulsified (1:1)
in IFA or 100 μg guinea pig MBP63–88 peptide in PBS emulsified (1:1) with CFA containing 0.5 mg MTB. The rats were monitored daily for clinical
signs of EAE, from day 7 until the day of sacrifice, at day 56 after immunization
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Fig. 3 T cell response in DA rats 28 days after MOG immunization. The DA rats were immunized with 20 μg MOG and 28 days later, the spleen
and deep cervical lymph nodes were excised and the cells stimulated with a medium, rrNF, and MOG. T cell proliferation was measured by H3
thymidine incorporation and displayed as scintillation (CPM counts per minute). The statistical significance in the T cell response between
the medium and rrNF was calculated by using non-parametric Mann-Whitney test in GraphPad Prism 5.0. *p < 0.05. Error bars represent
standard error of the mean (SEM)
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interval of the chromosome 3 QTL covers 70 to 161 Mb
and, therefore, harbors a large number of genes that might
be responsible for this effect on epitope spreading to in-
volve neurofascin in MOG-induced EAE. Neurofascin-
specific IgG, IgG1 (Th2 associated [23, 24]) and IgG2b
(Th1 associated [23]) levels were assessed by ELISA using
the sera collected at day 35 p.i. This revealed that anti-
rrNF IgG and IgG2b responses were significantly higher
in the diseased compared to the healthy DA backcross rats
(IgG 7.59 ± 0.39 vs. 5.1 ± 0.42, p < 0.001; IgG2b 2.9 ± 0.25
vs. 1.9 ± 0.19, p < 0.0001) (Fig. 5). Furthermore, this rrNF-
reactive IgG response in animals with EAE was asso-
ciated with increased disease severity as demonstrated
using maximum (MAX) (p < 0.01) and cumulative dis-
ease (SUM) scores (p < 0.05), disease duration (DUR)
(p < 0.05), and greater weight loss (WL0) (p < 0.05)
(Fig. 6). However, no effect on time of disease onset
was seen, an observation compatible with the involve-
ment of this response at later stages of disease (Fig. 6).
Furthermore, the rats with anti-rrNF IgG2b isotype-
specific reactivity exhibited a trend (p < 0.1) for higher
maximum score compared to rats that had no anti-
rrNF IgG2b response (Additional file 6: Figure S4).
The difference in rrNF-specific IgG1 antibodies was not
statistically significant between these two groups (Fig. 6).
Discussion
Epitope spreading has been suggested to be respon-
sible for relapses in EAE and also leads to increased
disease severity and chronicity [15]. While this con-
cept has been generally discussed with respect to T
cell reactivities, we hereby demonstrate that this ex-
tends to the B cell response in the MOG-induced
EAE model, that this response correlates with disease
severity, and that is genetically regulated. While we
do not address the relapse aspect, our data strongly
supports that the presence of an anti-neurofascin re-
sponse correlates with heightened disease severity, im-
plying that either anti-neurofascin response might
contribute to pathology directly or that simply epi-
tope spreading to neurofascin is a reflection of an ex-
acerbated disease per se. While MS is characterized
by both demyelination and direct damage to axons/
neurons [25], it is currently not completely clear what
leads to axonal injury. Epitope spreading to axonal
antigens, among other factors, might account for the
neurodegenerative processes and axonal pathology seen in
the late, progressive forms of the disease. Such a scenario
is consistent with the previous observations of a more fre-
quent presence of anti-neurofascin antibodies in progres-
sive MS [14].
Epitope spreading likely results from the loss of
self-tolerance [26] driven by tissue damage resulting
in increased availability of autoantigens in an inflam-
matory context. Our data support this concept in that
little or no spread to MOG or rrNF-specific B cell re-
sponses was observed in the animals with MBP63–88
induced disease. The fact that disease in the MBP
model is transient prevents us from drawing more ex-
tensive conclusions in this respect since chronic in-
flammation in the absence of demyelination might
also result in epitope spreading. Nonetheless, it is at-
tractive to consider that extensive demyelination in an
inflammatory context such as seen in MOG-induced
EAE is required to break/disrupt self-tolerance to
neurofascin and other myelin-associated autoantigens.
Neurofascin exists in two isoforms: neurofascin 186
(NF186), a neuronal protein that clusters with voltage-
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gated Na + channels at the node of Ranvier and plays
an important role in saltatory conduction; neurofascin
155 (NF155), an oligodendroglial/myelin protein that
maintains the structure of the paranodal junctional
complex [27]. In the present study, we do not distin-
guish between these two isoforms although our data
demonstrate that both are recognized by components
of the rrNF-reactive repertoire. Previous studies dem-
onstrate that such antibodies are able to mediate
axonal injury by binding to NF186 exposed at the
node of Ranvier [6, 14], but whether this mechanism
contributes significantly to enhance disease activity in
seropositive animals in our study is an open question.
Furthermore, we have observed that the antibody re-
sponse to rrNF cross-reacts with another member of
the Ig superfamily, TAG-1, a recently identified target
in MS, which elicits an encephalitogenic T cell re-
sponse selectively targeting gray matter tracts in ex-
perimental animals [22]. If the immune response to
these proteins does overlap, it might mean that to-
gether they constitute a molecular hot spot for the
development of autoaggressive responses targeting the
nodal domains of myelinated axons, but at the same
time raises the question as to which might be the pri-
mary or dominant target.
It should also be noted that while our data in the DA
backcross population demonstrate a significant associ-
ation between the presence of rrNF-specific IgG/IgG2b
responses and disease severity, this may simply reflect
that epitope spreading to neurofascin is a consequence
rather than a cause of exacerbated disease.
However, irrespective of the pathological significance
of the rrNF-specific response in animals with MOG-
EAE, our genome-wide linkage analysis demonstrates
that this is at least in part controlled by a QTL on
chromosome 3 that regulates the rrNF-specific IgG2b
response. This technique does not allow fine-mapping
down to the level of single genes and requires valid-
ation. However, this locus on chromosome 3 overlaps
with a QTL we demonstrated previously to regulate
EAE severity and the MOG-specific IgG response dur-
ing the later phase of EAE in the same DA backcross
population [20, 28]. Similarly in a (DAxPVG) x PVG
backcross study, this locus was linked to the MOG-
specific IgG2c response and disease severity [20, 28],
while the same QTL showed a strong linkage to disease
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severity and MOG-specific IgG and IgG2b levels in the
10th generation of a DAxPVG advanced intercross line
[20, 28]. In rats, IgG2b and IgG2c are associated with
the activation of Th1 dependent responses [23] that ac-
tively participate in the induction of EAE, as opposed
to IgG1 that is associated with Th2 reactivity [23, 24].
These observations imply that the genetic polymor-
phisms in the locus identified on chromosome 3 may in-
fluence the development of Th1-associated autoantibody
responses in general, rather than mediating a neurofascin-
specific effect, and thereof regulate EAE severity.
Conclusions
In summary, we demonstrate that epitope spreading
to involve neurofascin occurs preferentially in MOG-
induced EAE and report that this neurofascin-specific
response is associated with increased disease severity
and is under genetic regulation. While a role for T
cell immunity is well established, the functional sig-
nificance of antibodies remains controversial. Specific-
ally, it remains to be clarified whether autoantibody
responses to specific targets play a significant role in
driving disease development directly or reflect on-
going activation of the B cell compartment to provide
a pool of antigen presenting cells that exacerbates T
cell-mediated inflammation within the CNS. Elucidation
of pathophysiological significance of neurofascin-specific
antibodies in MOG-induced EAE may clarify this issue
and, in addition, permit the stratification of patients into
additional subtypes of disease.
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